Imunon sets R&D Day to spotlight IMNN-001 clinical progress
IMNN•Imunon to host R&D Day in New York City
Imunon will host an R&D Day in New York City on Sept. 23, 2026, starting at 10:00 a.m. ET.
The event will highlight clinical progress for IMNN-001, its investigational IL-12 immunotherapy in advanced ovarian cancer.
Agenda includes trial and translational updates
The agenda includes updates on the Phase 3 OVATION 3 trial, the Phase 2 MRD study, translational data and a management strategy discussion.
